Inozyme Pharma Inc (NASDAQ: INZY) is -48.74% lower on its value in year-to-date trading and has touched a low of $0.72 and a high of $6.24 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The INZY stock was last observed hovering at around $1.35 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $1.42, the stock is 21.53% and 35.27% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.63 million and changing 5.19% at the moment leaves the stock -51.80% off its SMA200. INZY registered -68.51% loss for a year compared to 6-month loss of -64.50%.
The stock witnessed a 42.40% gain in the last 1 month and extending the period to 3 months gives it a 5.19%, and is 14.52% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 18.55% over the week and 16.61% over the month.
Inozyme Pharma Inc (INZY) has around 67 employees, a market worth around $91.68M and $0.00M in sales. Distance from 52-week low is 96.95% and -77.24% from its 52-week high. The company has generated returns on investments over the last 12 months (-203.72%).
The EPS is expected to grow by 13.97% this year
The shares outstanding are 64.47M, and float is at 43.75M with Short Float at 9.11%.
The top institutional shareholder in the company is ADAGE CAPITAL PARTNERS GP, L.L.C. with over 5.73 million shares valued at $25.55 million. The investor’s holdings represent 9.2484 of the INZY Shares outstanding. As of 2024-06-30, the second largest holder is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC with 4.49 million shares valued at $20.05 million to account for 7.2563 of the shares outstanding. The other top investors are SOFINNOVA INVESTMENTS, INC. which holds 4.28 million shares representing 6.91 and valued at over $19.09 million, while EVENTIDE ASSET MANAGEMENT, LLC holds 6.3545 of the shares totaling 3.94 million with a market value of $17.56 million.
Inozyme Pharma Inc (INZY) Insider Activity
The most recent transaction is an insider sale by Treco Douglas A, the company’s CEO & Chairman. SEC filings show that Treco Douglas A sold 8,819 shares of the company’s common stock on Apr 02 ’25 at a price of $0.89 per share for a total of $7849.0. Following the sale, the insider now owns 41046.0 shares.
